Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Poorer RCC outcomes with incidental upstaging after partial nephrectomy

Russell C et al. Urology; July 2018, 95-100. https://doi.org/10.1016/j.urology.2018.04.002

Key clinical point: Patients with incidental pathologic T3a (pT3a) upstaging after partial nephrectomy (PN) have significantly reduced recurrence-free survival (RFS) and cancer-specific survival (CSS) when compared to patients whose disease isn't upstages from pT1a-b.

Major finding: Of 1955 patients who had partial nephrectomies, 95 had pT3a upstaging. In those patients with pT3a upstaging, 3- and 5-year RFS were 81% and 58%, compared to 86% and 75% in pT1a-b controls (P = .01). CSS at 3 and 5 years was 91% and 90% in pT3a disease and 100% and 97% in pT1a-b controls (P less than .01). All-cause mortality at 3 and 5 years were 82% and 71% in pT3a disease and 93% and 80% in pT1a-b controls (P = .04).

Study details: Retrospective chart review was completed at the University of Michigan and Moffitt Cancer Center to identify patients undergoing PN for clinical T1 masses between 1995 and 2015. Patients with pT3a disease were individually matched by clinicopathologic features with patients undergoing PN with pT1a-b disease in a 1:2 ratio. Primary endpoint was recurrence-free survival (RFS). Secondary endpoints were all-cause mortality, cancer-specific survival (CSS), and rates of local and distant recurrence.

Disclosures: The authors had no relevant financial disclosures.

Source: Russell C et al. Urology; July 2018, 95-100. https://doi.org/10.1016/j.urology.2018.04.002

Citation:

Russell C et al. Urology; July 2018, 95-100. https://doi.org/10.1016/j.urology.2018.04.002

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Renal Cell Carcinoma

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617